{"id":886,"date":"2020-09-14T17:49:52","date_gmt":"2020-09-15T00:49:52","guid":{"rendered":"https:\/\/depts.washington.edu\/pandemicalliance\/?p=886"},"modified":"2020-09-14T17:49:52","modified_gmt":"2020-09-15T00:49:52","slug":"sars-cov-2-antibody-prevalence-and-association-with-routine-laboratory-values-in-a-life-insurance-applicant-population","status":"publish","type":"post","link":"https:\/\/depts.washington.edu\/pandemicalliance\/2020\/09\/14\/sars-cov-2-antibody-prevalence-and-association-with-routine-laboratory-values-in-a-life-insurance-applicant-population\/","title":{"rendered":"SARS-CoV-2 Antibody Prevalence and Association with Routine Laboratory Values in a Life Insurance Applicant Population"},"content":{"rendered":"<ul>\n<li>[Preprint, not peer-reviewed] Testing for SARS-CoV-2 antibodies indicates that the total number of SARS-CoV-2 infections in the US is 3.8-times higher than the total number of cases reported to the CDC. This estimate is based on a seropositivity rate of 3% among 50,130 consecutive life insurance applicants, which would correspond to 6.98 million SARS-CoV-2 infections when applied to state population data from the US Census as of June 1, 2020.<\/li>\n<\/ul>\n<p>Rigatti et al. (Sept 11, 2020). SARS-CoV-2 Antibody Prevalence and Association with Routine Laboratory Values in a Life Insurance Applicant Population. Pre-print downloaded September 14 from <a href=\"https:\/\/doi.org\/10.1101\/2020.09.09.20191296\">https:\/\/doi.org\/10.1101\/2020.09.09.20191296<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>[Preprint, not peer-reviewed] Testing for SARS-CoV-2 antibodies indicates that the total number of SARS-CoV-2 infections in the US is 3.8-times higher than the total number of cases reported to the CDC. This estimate is based on a seropositivity rate of 3% among 50,130 consecutive life insurance applicants, which would correspond to 6.98 million SARS-CoV-2 infections&#8230;<\/p>\n<div><a class=\"more\" href=\"https:\/\/depts.washington.edu\/pandemicalliance\/2020\/09\/14\/sars-cov-2-antibody-prevalence-and-association-with-routine-laboratory-values-in-a-life-insurance-applicant-population\/\">Read more<\/a><\/div>\n","protected":false},"author":5,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[6],"tags":[67],"topic":[19],"class_list":["post-886","post","type-post","status-publish","format-standard","hentry","category-article-summary","tag-antibodies","topic-testing-and-treatment"],"_links":{"self":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/886","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/comments?post=886"}],"version-history":[{"count":1,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/886\/revisions"}],"predecessor-version":[{"id":887,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/886\/revisions\/887"}],"wp:attachment":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/media?parent=886"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/categories?post=886"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/tags?post=886"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/topic?post=886"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}